The recognition of the biological role and therapeutic potential of immune checkpoint blockade (through CTLA-4 and PD-1 targeting) has revolutionized our approach to cancer immunotherapy, as also highlighted by the 2018 Nobel Prize award [11,37]. Here, CTLA4 is linked to cancer.